David P. Richman, M.D.

Clinical Interests
David P. Richman's professional interests include biochemistry and pharmacology of the nicotinic acetylcholine receptor and muscle-specific kinase (MuSK), diseases of neuromuscular transmission, myasthenia gravis, anti-MuSK myastemia, and Lambert-Eaton myasthenic syndrome, and the pathogenesis and control of autoimmune response in myasthenia gravis. Richman has coauthored an extensive list of publications and book chapters on neurological disease and related topics.

Title
Professor

Specialty
Neurology - Neuroimmunology, Myasthenia Gravis

Department
Neurology

Division
Neurology

Address/Phone
Lawrence J. Ellison Ambulatory Care Center, Neurology, 4860 Y St. Suite 0100 Sacramento, CA 95817
Phone: 916-734-3588

Additional Phone
Physician Referrals: 800-4-UCDAVIS (800-482-3284)

Education
M.D., Johns Hopkins University School of Medicine, Baltimore, Maryland, 1969
A.B., Princeton University, Princeton, New Jersey, 1965

Internships
Albert Einstein College of Medicine, New York City, New York, 1969-70

Residency
Albert Einstein College of Medicine, New York City, New York, 1970-71
Massachusetts General Hospital, Boston, Massachusetts, 1973-74

Fellowships
Harvard Medical School, Boston, Massachusetts, 1974-75
Massachusetts General Hospital, Boston , Massachusetts, 1974-76

Board Certifications
American Board of Psychiatry and Neurology, 1976

Professional Memberships
American Academy of Neurology
American Association for the Advancement of Science
American Association of Immunologists
American Neurological Association
National Myasthenia Gravis Foundation, Inc.

UCDAVIS HEALTH SYSTEM

David P. Richman, M.D.

Select Recent Publications

Richman DP, Nishi K, Morell SW, Chang JM, Ferns MJ, Wollmann RL, Maselli RA, Schnier J, Agius MA. Acute severe animal model of anti-muscle-specific kinase myasthenia: combined postsynaptic and presynaptic changes. *Arch Neurol.* 2012 Apr;69(4):453-60. Epub 2011 Dec 12.

Richman DP. Antibodies to low density lipoprotein receptor-related protein 4 in seronegative myasthenia gravis. *Arch Neurol.* 2012 Apr;69(4):434-5. Epub 2011 Dec 12.

Wong VS, Adamczyk P, Dahlin B, Richman DP, Wheelock V. Cerebral venous sinus thrombosis presenting with auditory hallucinations and illusions. *Cogn Behav Neurol.* 2011 Mar;24(1):40-2.

Kim JY, Park KD, Richman DP. Treatment of myasthenia gravis based on its immunopathogenesis. *J Clin Neurol.* 2011 Dec;7(4):173-83. Epub 2011 Dec 29.

Kim SS, Richman DP, Zamvil SS, Agius MA. Accelerated central nervous system autoimmunity in BAFF-receptor-deficient mice. *J Neurol Sci.* 2011 Jul 15;306(1-2):9-15. Epub 2011 May 6.

Anderson JA, Ng JJ, Bowe C, McDonald C, Richman DP, Wollmann RL, Maselli RA. Variable phenotypes associated with mutations in DOK7. *Muscle Nerve.* 2008 Apr;37(4):448-56.

Sanders DB, Hart IK, Mantegazza R, Shukla SS, Siddiqi ZA, De Baets MH, Melms A, Nicolle MW, Solomons N, Richman DP. An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis. *Neurology.* 2008 Aug 5;71(6):400-6. Epub 2008 Apr 23.

Richman DP, Agius MA. Treatment of autoimmune myasthenia gravis. *Neurology.* 2003 Dec 23;61 (12):1652-61.

Maselli RA, Kong D, Bowe C, McDonald C, Ellis W, Agius MA, Gomez CM, Richman DP, Wollmann RL. Presynaptic congenital myasthenic syndrome due to quantal release deficiency. *Neurology* 57: 279-289, 2001.

Roberts PF, Venuta F, Rendina E, De Giancomo T, Coloni GF, Follette DM, Richman DP, Benfield JR. Thymectomy in the treatment of ocular myasthenia gravis. *J. Thor. Cardiovasc. Surg.* 122: 562-8, 2001.

Richman DP, Agius MA, Kirvan CA, Gomez CM, Fairclough RH, DuPont BL, Maselli RA. Antibody effector mechanisms in myasthenia gravis: the complement hypothesis Annals of New York Academy of Science 1998;841: 450-465

Fairclough RH, Twaddle GM, Gudipati E, Lin MY, Richman DP. Differential surface accessibility of a(187-199) in the Torpedo acetylcholine receptor a subunits. *J. Mol. Biol.* 282:317-330, 1998.

Fairclough, R.H., Twaddle, G.M., Gudipati, E., Richman, D.P., Burkwall, D.A., and Josephs R. Mapping the mAb 383C epitope to a2(187-199) of the Torpedo acetylcholine receptor on the three dimensional model. J. Mol. Biol. 282:301-315, 1998.

UCDAVIS HEALTH SYSTEM

David P. Richman, M.D.

UCDAVIS
HEALTH SYSTEM